Prometheus Laboratories Inc., a leader in precision healthcare, has expanded its PredictrPK platform with the launch of precision-guided dosing tests for vedolizumab (VDZ) and ustekinumab (UST) in adult patients with inflammatory bowel disease. The company now offers precision-guided dosing tests for four of the most widely used biologics in IBD treatment: adalimumab, infliximab, vedolizumab, and ustekinumab.
Addressing Treatment Variability Through Drug Clearance
Healthcare providers commonly observe significant variability in patient responses to biologic therapies like VDZ and UST. While traditional therapeutic drug monitoring provides information on drug levels and antidrug antibodies, it fails to fully explain treatment failures or loss of response over time and doesn't offer insights into alternative dosing strategies.
The PredictrPK tests address these limitations by incorporating drug clearance as a key output parameter. By combining drug clearance measurements with serum biologic concentrations and antidrug antibodies through pharmacokinetic modeling, Prometheus provides healthcare providers with personalized alternative dosing guidance. This approach enables clinicians to optimize biologic exposure while avoiding ineffective treatment cycles that contribute to healthcare cost inefficiencies.
Clinical Evidence Supporting Clearance-Based Dosing
At Digestive Disease Week 2025 Congress, Prometheus's research and development team presented data exploring the impact of patient pharmacokinetics on treatment outcomes. Drug clearance emerged as significantly associated with disease control in IBD patients. Notably, higher VDZ drug clearance above the established cutoff was associated with 9-fold and 2-fold lower likelihood of endoscopic as well as clinical and biochemical remission, respectively, in Crohn's disease patients.
"The expansion of the PredictrPK platform to include VDZ and UST is based on growing evidence that drug clearance in combination with concentrations is a key determinant of therapeutic response in IBD," said Patricia Vasquez, President of Prometheus. "Our internal analyses and recent collaborative studies from our research and development team have consistently shown that patients with higher clearance are less likely to achieve clinical and endoscopic remission."
Validated Clinical Utility in Real-World Settings
A prospective, cross-sectional multi-center clinical experience study published in Pharmaceutics demonstrated the clinical utility of PredictrPK ADA for optimizing adalimumab therapy in IBD patients. The study assessed 213 cases from a diverse IBD patient population by 21 healthcare providers in the United States.
The study found that PredictrPK enabled early and more precise optimization of adalimumab therapy by predicting future trough levels at alternative doses and intervals at any time during the therapy cycle. Over half of patients demonstrated accelerated clearance, putting them at risk of inadequate drug exposure or antidrug antibody formation and highlighting the need for potential intervention or close monitoring.
"Precision-guided dosing allows us to tailor adalimumab therapy to the unique pharmacokinetic and clinical characteristics of each patient, to help achieve better disease control, reduce the likelihood of therapy discontinuation, or expedite a therapy switch, when necessary," said study lead Dr. Stephen B. Hanauer, MD, FACG, Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University's Feinberg School of Medicine.
Strong Provider Adoption and Clinical Impact
Results from the post-program survey underscored the effectiveness of PredictrPK, with 81 percent of healthcare providers indicating it helped them select the optimal adalimumab dose and/or interval, and 81 percent finding it helpful in discussions with patients regarding dose escalation.
The PredictrPK tests combine serology markers, patient-specific variables, current dosing, and proprietary pharmacokinetic Bayesian forecast modeling to calculate drug clearance and help providers optimize dosing for individual IBD patients. The platform provides predicted drug levels for both current and alternate doses and therapy intervals, enabling precise, individualized dosing to aid patients in achieving and retaining remission with biologics in less time.
Prometheus Laboratories has operated as a leading specialty clinical laboratory for 30 years, focusing on precision medicine tests that improve healthcare outcomes for individuals with immune-mediated and gastrointestinal diseases by empowering providers to diagnose, treat, and help patients achieve remission faster through precision-guided care.
